story of the week
Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With HR+, HER2− Metastatic Breast Cancer Resistant to Aromatase Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
J. Clin. Oncol 2018 Apr 17;[EPub Ahead of Print], N Kornblum, F Zhao, J Manola, P Klein, B Ramaswamy, A Brufsky, PJ Stella, B Burnette, M Telli, DF Makower, P Cheema, CI Truica, AC Wolff, GS Soori, B Haley, TR Wassenaar, LJ Goldstein, KD Miller, JA SparanoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.